BAF312 is a selective agonist for S1P1 and S1P5 [2]; in the USA, it was approved for the treatment of relapsing forms of MS, including clinically isolated syndrome, RRMS, and secondary progressive (SP) MS, and in Europe for SPMS with clinical/radiological evidence of disease activity. Here, S1PR1 is linked to myeloid sarcoma.